ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals Inc (LBPH)

59.78
0.01
( 0.02% )
Updated: 11:15:21

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
59.78
Bid
59.77
Ask
59.78
Volume
449,650
59.76 Day's Range 59.80
3.60 52 Week Range 59.95
Market Cap
Previous Close
59.77
Open
59.77
Last Trade
20
@
59.77
Last Trade Time
11:16:14
Financial Volume
$ 26,876,577
VWAP
59.7722
Average Volume (3m)
1,786,654
Shares Outstanding
39,045,703
Dividend Yield
-
PE Ratio
-42.88
Earnings Per Share (EPS)
-1.39
Revenue
-
Net Profit
-54.42M

About Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659. Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Longboard Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LBPH. The last closing price for Longboard Pharmaceuticals was $59.77. Over the last year, Longboard Pharmaceuticals shares have traded in a share price range of $ 3.60 to $ 59.95.

Longboard Pharmaceuticals currently has 39,045,703 shares outstanding. The market capitalization of Longboard Pharmaceuticals is $2.33 billion. Longboard Pharmaceuticals has a price to earnings ratio (PE ratio) of -42.88.

LBPH Latest News

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be activated in the coming weeks Longboard...

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated...

Kuehn Law Encourages PRMW, FBMS, EVRI, and LBPH Investors to Contact Law Firm

Kuehn Law Encourages PRMW, FBMS, EVRI, and LBPH Investors to Contact Law Firm PR Newswire NEW YORK, Oct. 15, 2024 NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10059.7859.86559.47176384177959.7531181CS
40.320.53817692566459.4659.9558.8284345759.69497599CS
1224.5569.684927618535.2359.9527.35178665453.64464883CS
2638.95186.98991838720.8359.9515.64111838947.86233638CS
5255.521303.286384984.2659.953.6100193436.86196974CS
15653.61868.8816855756.1759.952.736238134.39319084CS
26043.78273.6251659.952.730395333.58849899CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 1.892
(93.06%)
105.42M
CRNCCerence Inc
$ 5.17
(83.33%)
32.73M
BDRXBiodexa Pharmaceuticals PLC
$ 6.13
(59.22%)
3.73M
IBGInnovation Beverage Group Limited
$ 1.1309
(42.93%)
6.83M
SPAISafe Pro Group Inc
$ 4.4871
(40.22%)
38.45M
PYXSPyxis Oncology Inc
$ 2.055
(-46.20%)
9.59M
GLXGGalaxy Payroll Group Ltd
$ 2.20
(-43.73%)
507.51k
KURAKura Oncology Inc
$ 9.99
(-37.21%)
7.54M
BLRXBioLineRx Ltd
$ 0.3571
(-34.50%)
5.72M
SHOTWSafety Shot Inc
$ 0.1001
(-33.27%)
2.5k
CDTConduit Pharmaceuticals Inc
$ 0.1109
(20.15%)
490.48M
NVDANVIDIA Corporation
$ 143.81
(-1.43%)
205.05M
AKTSAkoustis Technologies Inc
$ 0.1014
(16.42%)
183.54M
ELABElevai Labs Inc
$ 0.0201
(-6.07%)
150.44M
WORXSCWorx Corporation
$ 1.892
(93.06%)
105.42M

LBPH Discussion

View Posts
TechandBio TechandBio 1 month ago
Yup Their it is like I said got to see the angles before they are played! Unreal!

Now I get to buy some more beaten down bios for my kid.

Denmark's Lundbeck bets on epilepsy drug in $2.6 billion Longboard deal

1000% gains+ for the year here!

$LBPH
πŸ‘οΈ0
tw0122 tw0122 1 month ago
Time to take profits at $55 … Longboard shareholders will be offered a payment of USD 60.00 per share in cash. The transaction is valued at approximately USD 2.6 billion equity value and USD 2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis.
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
LBPH trending sideways again
πŸ‘οΈ0
FALCON1 FALCON1 4 months ago
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
πŸ‘οΈ0
TechandBio TechandBio 4 months ago
MY best performing Bio this year! Surfs up Vertical debit spreads from $5.00 are up over 1430% wish i went heavier keep an eye on ICCM

$LBPH
πŸ‘οΈ0
da_stock_analyst da_stock_analyst 10 months ago
#LBPH 🔥 short squeeze might push this way higher! Nice set up!
πŸ‘οΈ0
Backstabbed Backstabbed 11 months ago
Insane … grats all
πŸ‘οΈ0
conix conix 11 months ago
LOTTO Ticket for 2024: Curative Biotechnology $CUBT @ $0.02 is a biotech with some very promising technology in the treatment of Age-Related Macular Degeneration (AMD). Metformin, a widely used diabetes drug, has been proven to have positive effects on patients with AMD. CUBT has a patented formulation for the direct delivery of metformin to the eye in the form of eye drops. The National Institutes of Health (NIH) will be funding a clinical trial on humans in 2024 in collaboration with the company. There has been a number of delays in the start of the trials, hence the low price, but the price has been firming up this past month. Although difficult to predict when these announcements happen, at these prices, CUBT is worth buying a small position (you can define "small") to make certain you are following the news and the price reaction so you can average up on your original position. Check the CUBT website out to see more info on the trials and the company's other drugs in the pipeline. Target Price by end of First Quarter (assuming clinical trial announcement)--$0.15).

SOURCE: https://www.reddit.com/r/pennystocks/comments/18uvm1j/trading_ideas_for_january_sing_migi_cubtmentioned/

It should go without saying, BUT some may need to read it...the above is someone's opinion. Nice to see anyways.
πŸ‘οΈ0
conix conix 11 months ago
Congrats on being a quick thinker. Per-market buying can be risky, but does pan out.
πŸ‘οΈ0
TheFinalCD TheFinalCD 11 months ago
The company has 9.5 months of cash left based on quarterly cash burn of -$13.28M and estimated current cash of $42.0M.
https://dilutiontracker.com/app/search/LBPH?a=dbb88c
πŸ‘οΈ0
Stockexpertpro Stockexpertpro 11 months ago
AVTX Data Due on Watch here after 1 for 240 RS micro Float
πŸ‘οΈ0
Laster Laster 11 months ago
Grabbed some at 8am immediately following news.
Looking good moving into open.
Sold half on double. Riding rest free.
What a way to start 2024!
πŸ‘οΈ0
Monksdream Monksdream 11 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
tw0122 tw0122 11 months ago
An epileptic profit nice…
πŸ‘οΈ0
cityimport cityimport 11 months ago
My First Almost 200% Profit (Within One Hour) In 2024 ... :)))))))))))))

In @ 6.25
Out @ 17.95

LBPH
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock